Key result
Rivaroxaban was evaluated for thromboprophylaxis in acutely ill medical patients, but the provided abstract lacks specific clinical findings.
Key points are not available for this paper at this time.
Lacks specific outcomes for rivaroxaban thromboprophylaxis; leaves open its role in acutely ill patients pending fuller data.
Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056-NEJMoa1111096; Eriksson BI, 2008, NEW ENGL J MED, V358, P2765, DOI 10.1056-NEJMoa0800374; Lassen MR, 2008, NEW ENGL J MED, V358, P2776, DOI 10.1056-NEJMoa076016
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2013) studied this question. Rivaroxaban was evaluated for thromboprophylaxis in acutely ill medical patients, but the provided abstract lacks specific clinical findings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: